Virtual Screening and Molecular Dynamics Simulation to Identify Inhibitors of the m6A-RNA Reader Protein YTHDC1
Source abstract
Abstract
YTHDC1 (YTH domain containing 1), a crucial reader protein of N6-methyladenosine (m6A) mRNA, plays a critical role in various cellular functions and is considered a promising target for therapeutic intervention in acute myeloid leukemia and other cancers. In this study, we identified orthosteric small-molecule ligands for YTHDC1. Using a molecular docking approach, we screened the eMolecules database and recognized 15 top-ranked ligands. Subsequently, molecular dynamics simulations and MM/PBSA analysis were used to assess the stability and binding free energy of these potential hit compounds in complex with YTHDC1. Notably, five compounds with IDs of ZINC82121447, ZINC02170552, ZINC65274016, ZINC10763862, and ZINC02412146 exhibited high binding affinities and favorable binding free energies. The results also showed that these compounds formed strong hydrogen bonds with residues SER378, ASN363, and ASN367 and interacted with the aromatic cage of the YTHDC1 reader protein through TRP377, TRP428, and hydrophobic residue LEU439. To assess their viability as lead compounds, we conducted absorption, distribution, metabolism, excretion, and toxicity (ADMET) studies to reveal promising features for these identified small molecules, shedding light on their pharmacokinetic and safety profiles.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA modifications and cancer · RNA and protein synthesis mechanisms · RNA Research and Splicing
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute for Advanced Study, Shenzhen University, Shenzhen 518060, China
Funding
Shenzhen Science and Technology Innovation Commission · Natural Science Foundation of Guangdong Province, China
References (81)
Show source-provided references
1. m6A modification: Recent advances, anticancer targeted drug discovery and beyond10.1186/s12943-022-01510-2 ↗
2. Grand challenge commentary: RNA Epigenetics?10.1038/nchembio.482 ↗
3. Saletore, Y., Meyer, K., Korlach, J., Vilfan, I.D., Jaffrey, S., and Mason, C.E. (2012). The birth of the Epitranscriptome: Deciphering the function of RNA Modifications. Genome Biol., 13.10.1186/gb-2012-13-10-175 ↗
4. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells10.1073/pnas.71.10.3971 ↗
5. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq10.1038/nature11112 ↗
6. Gene expression regulation mediated through reversible m6A RNA methylation10.1038/nrg3724 ↗
7. N6-methyladenosine-encoded epitranscriptomics10.1038/nsmb.3162 ↗
8. Where, when, and how: Context-dependent functions of rna methylation writers, readers, and erasers10.1016/j.molcel.2019.04.025 ↗
9. Dynamic transcriptomic m(6)A decoration: Writers, erasers, readers and functions in RNA metabolism10.1038/s41422-018-0040-8 ↗
10. Post-transcriptional gene regulation by mRNA modifications10.1038/nrm.2016.132 ↗
11. The m6A-epitranscriptomic signature in neurobiology: From neurodevelopment to brain plasticity10.1111/jnc.14481 ↗
12. Dynamic m6A mRNA methylation directs translational control of heat shock response10.1038/nature15377 ↗
13. N6-methyladenosine of chromosome-associated regulatory RNA regulates chromatin state and transcription10.1126/science.aay6018 ↗
14. Epitranscriptomic addition of m6A regulates HIV-1 RNA stability and alternative splicing10.1101/gad.348508.121 ↗
15. m6A modification controls the innate immune response to infection by targeting type I interferons10.1038/s41590-018-0275-z ↗
16. Novel insights on m6A RNA methylation in tumorigenesis: A double-edged sword10.1186/s12943-018-0847-4 ↗
17. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine, methylation10.1038/nchembio.1432 ↗
18. The potential role of RNA N6-methyladenosine in Cancer progression10.1186/s12943-020-01204-7 ↗
19. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis10.1038/cr.2014.151 ↗
20. Nuclear m(6)A reader YTHDC1 regulates mRNA splicing10.1016/j.molcel.2016.01.012 ↗
21. Structural imprints in vivo decode RNA regulatory mechanisms10.1038/nature14263 ↗
22. YTHDC1 mediates nuclear export of N6-methyladenosine methylated mRNAs10.7554/eLife.31311 ↗
23. N(6)-methyladenosine modulates messenger RNA translation efficiency10.1016/j.cell.2015.05.014 ↗
24. N6-methyladenosine marks primary microRNAs for processing10.1038/nature14281 ↗
25. Roles and mechanisms of the m6A reader YTHDC1 in biological processes and diseases10.1038/s41420-022-01040-2 ↗
26. m6A-binding proteins: The emerging crucial performers in epigenetics10.1186/s13045-020-00872-8 ↗
27. Structural basis for selective binding of m6A RNA by the YTHDC1 YTH domain10.1038/nchembio.1654 ↗
28. Xu, Y., Zhang, W., Shen, F., Yang, X., Liu, H., Dai, S., Sun, X., Huang, J., and Guo, Q. (2021). YTH Domain Proteins: A Family of m6A Readers in Cancer progression. Front. Oncol., 11.10.3389/fonc.2021.629560 ↗
29. m6A modification of circHPS5 and hepatocellular carcinoma progression through HMGA2 expression10.1016/j.omtn.2021.09.001 ↗
30. N6-methyladenosine modification of circular RNA circ-ARL3 facilitates Hepatitis B virus-associated hepatocellular carcinoma via sponging miR-130510.1002/iub.2438 ↗
31. EMP3 negatively modulates breast cancer cell DNA replication, DNA damage repair, and stem-like properties10.1038/s41419-021-04140-6 ↗
32. Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma10.1038/s41586-019-0993-x ↗
33. N6-methyladenosine-modified circIGF2BP3 inhibits CD8 T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer10.1186/s12943-021-01398-4 ↗
34. N6-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation10.1016/j.ccell.2021.04.017 ↗
35. Molecular docking and structure-based drug design strategies10.3390/molecules200713384 ↗
36. Singh, N., Ying, S.-Q., and Li, W. (2021). Identification of novel inhibitors of type-I mycobacterium tuberculosis fatty acid synthase using docking-based virtual screening and molecular dynamics simulation. Appl. Sci., 11.10.3390/app11156977 ↗
37. Molecular dynamics simulations in drug design10.1007/978-1-62703-342-8_7 ↗
38. Rigorous free energy simulations in virtual screening10.1021/acs.jcim.0c00116 ↗
39. Poli, G., Granchi, C., Rizzolio, F., and Tuccinardi, T. (2020). Application of MM/PBSA methods in virtual screening. Molecules, 25.10.3390/molecules25081971 ↗
40. METTL3 inhibitors for Epitranscriptomic modulation of cellular processes10.1002/cmdc.202100291 ↗
41. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia10.1038/s41586-021-03536-w ↗
42. 1,4,9-Triazaspiro[5.5]Undecan-2-One derivatives as potent and selective METTL3 inhibitors10.1021/acs.jmedchem.1c00773 ↗
43. Selectively disrupting M6A-dependent protein–RNA interactions with fragments10.1021/acschembio.9b00894 ↗
44. Structure-based design of ligands of the M6A-RNA reader YTHDC1
45. Atomistic and thermodynamic analysis of N6-Methyladenosine (M6A) recognition by the reader Domain of YTHDC110.1021/acs.jctc.0c01136 ↗
46. Structure-based design of a potent and selective YTHDC1 ligand10.1021/acs.jmedchem.4c00599 ↗
47. Abstract 3231: Pharmacological inhibition of the m6A RNA reader, YTHDC1, as a novel approach to targeting biomolecular condensates in cancer10.1158/1538-7445.AM2024-3231 ↗
48. Selberg, S., Yu, L.Y., Bondarenko, O., Kankurim, E., Seli, N., Kovaleva, V., Herodes, K., Saarma, M., and Karelson, M. (2021). Small-molecule inhibitors of the RNA M6A demethylases FTO potently support the survival of dopamine neurons. Int. J. Mol. Sci., 22.10.1101/2021.02.23.432419 ↗
49. The Fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain circuitry10.1038/nn.3449 ↗
50. Synthesis of a FTO inhibitor with anticonvulsant activity10.1021/cn500042t ↗
51. Meclofenamic acid selectively inhibits FTO demethylation of M6A over ALKBH510.1093/nar/gku1276 ↗
52. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia10.1016/j.ccell.2019.03.006 ↗
53. Fragment ligands of the m6A-RNA reader YTHDF210.1021/acsmedchemlett.2c00303 ↗
54. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading10.1002/jcc.21334 ↗
55. Surflex: Fully automatic flexible molecular docking using a molecular similarity-based search engine10.1021/jm020406h ↗
56. UCSF Chimera—A visualization system for exploratory research and analysis10.1002/jcc.20084 ↗
57. (BIOVIA, DS, 2022). BIOVIA, DS, version 22.1.
58. GROMACS: Fast, flexible, and free10.1002/jcc.20291 ↗
59. Automation of the CHARMM general force field (CGenFF) I: Bond perception and atom typing10.1021/ci300363c ↗
60. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields10.1002/jcc.21367 ↗
61. H++ 3.0: Automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulation10.1093/nar/gks375 ↗
62. DelPhiPKa web server: Predicting pKa of proteins, RNAs and DNAs10.1093/bioinformatics/btv607 ↗
63. Structure and dynamics of the TIP3P, SPC, and SPC/E Water models at 298 K10.1021/jp003020w ↗
64. Polymorphic transitions in single crystals: A new molecular dynamics method10.1063/1.328693 ↗
65. Canonical sampling through velocity rescaling10.1063/1.2408420 ↗
66. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems10.1063/1.464397 ↗
67. New spherical-cutoff methods for long-range forces in macromolecular simulation10.1002/jcc.540150702 ↗
68. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF9410.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P ↗
69. Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Scalmani, G., Barone, V.P., Mennucci, B., and Petersson, G.A. (2016). Gaussian 09, Revision C.01, Gaussian, Inc.
70. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: The RESP model10.1021/j100142a004 ↗
71. The Amber biomolecular simulation programs10.1002/jcc.20290 ↗
72. ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB10.1021/acs.jctc.5b00255 ↗
73. Assessing the performance of MM/PBSA and MM/GBSA methods. 3. The impact of force fields and ligand charge models10.1021/jp404160y ↗
74. The Nose-Hoover thermostat10.1063/1.449071 ↗
75. Docking and ligand binding affinity: Uses and pitfalls
76. Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking10.1002/jcc.21666 ↗
77. g_mmpbsa—A GROMACS tool for high-throughput MM/PBSA calculations10.1021/ci500020m ↗
78. Computing clinically relevant binding free energies of HIV-1 protease inhibitors10.1021/ct4007037 ↗
79. Comparative assessment of scoring functions: The CASF-2016 update10.1021/acs.jcim.8b00545 ↗
80. Singh, N., and Li, W. (2020). Absolute binding free energy calculations for highly flexible protein MDM2 and its inhibitors. Int. J. Mol. Sci., 21.10.3390/ijms21134765 ↗
81. Efficient drug lead discovery and optimization10.1021/ar800236t ↗